Severe and/or active co-morbidity defined as follows:\r\n* History of inflammatory bowel disease\r\n* History of active hepatitis B or C; blood tests are not required to determine if the patient has had hepatitis B or C, unless the patient reports a history of hepatitis\r\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last  months\r\n* Transmural myocardial infarction within the last  months\r\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of step  registration\r\n* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization within  days of step  registration or precluding study therapy at the time of step  registration\r\n* Uncontrolled severe illness or medical condition (including uncontrolled diabetes), which in the judgment of the treating physician would make the administration of chemotherapy inadvisable
Severe, active co-morbidity defined as follows:\r\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last  months\r\n* Transmural myocardial infarction within the last  months\r\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\r\n* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
Major medical illnesses or psychiatric impairments, which in the investigators opinion, will prevent administration or completion of the protocol therapy and/or preclude informed consent; these include, but are not restricted to:\r\n* Unstable angina and/or congestive heart failure requiring hospitalization at the time of step  registration\r\n* Transmural myocardial infarction within the last  months prior to step  registration\r\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of step  registration\r\n* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of step  registration\r\n* Type II neurofibromatosis (NF)\r\n* Ailments entailing substantial increases in sensitivity and side effect risk from radiation therapy (ataxia telangiectasia, Nijmegen breakage syndrome, and human immunodeficiency virus (HIV) with CD count <  cells/microliter); HIV testing is not required for eligibility for this protocol, and known HIV positive patients are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD count >=  cells/microliter within  days prior to step  registration\r\n* Inability to undergo MRI with and without contrast (e.g. claustrophobia, non-MRI compatible implant or foreign body, etc) or receive gadolinium; note that patients with severe claustrophobia are permitted on this study if they are willing and able to undergo MRI with adequate sedation or anesthesia
Severe, active comorbidity, defined as follows:\r\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last  months\r\n* Transmural myocardial infarction within the last  months\r\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\r\n* Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects\r\n* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration\r\n* Uncontrolled, clinically significant cardiac arrhythmias\r\n* Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD) count <  cells/microliter\r\n** Note: patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD count >=  cells/microliter within  days prior to Step  registration\r\n** Note: HIV testing is not required for eligibility for this protocol
Severe, active co-morbidity, defined as follows:\r\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last  months prior to registration;\r\n* Transmural myocardial infarction within the last  months prior to registration;\r\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration;\r\n* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within  days prior to registration;\r\n* Severe hepatic disease, defined as a diagnosis of Child-Pugh class B or C hepatic disease if the liver is involved with metastatic disease;\r\n* Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD) count <  cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD count >=  cells/microliter within  days prior to registration; note also that HIV testing is not required for eligibility for this protocol
Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within  days of registration;
Severe, active co-morbidity, defined as follows:\r\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last six months\r\n* Transmural myocardial infarction within the last six months\r\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\r\n* Chronic obstructive pulmonary disease exacerbation or other chronic respiratory illness requiring hospitalization within the last six months\r\n* Human immunodeficiency virus (HIV)-positivity with cluster of differentiation (CD) count <  cells/microliter; Note that HIV-positive patients are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD count >=  cells/microliter no more than  days prior to registration; Note also that HIV testing is not required for eligibility on this protocol\r\n* End-stage renal disease (i.e., any patient requiring or advised to undergo dialysis)
Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
Respiratory illness requiring hospitalization at the time of step  registration\r\n* Note: if the respiratory illness is resolved and the patient meets the eligibility status above, then the patient can be considered for the trial
Severe, active co-morbidity, defined as follows:\r\n* Diagnosis of type I or type II diabetes mellitus\r\n* Uncontrolled neuropathy >= grade  regardless of cause\r\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last  months\r\n* Transmural myocardial infarction within the last  months\r\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\r\n* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within  days of registration\r\n* Severe hepatic disease, defined as a diagnosis of Child-Pugh class B or C hepatic disease\r\n* Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD) count <  cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD count >=  cells/microliter within  days prior to registration; note also that HIV testing is not required for eligibility for this protocol\r\n* End-stage renal disease (ie, on dialysis or dialysis has been recommended)
Severe, active co-morbidity, defined as follows per time points indicated below (or per time points indicated below prior to the first day of chemotherapy for patients having started chemotherapy prior to first step registration): \r\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last  months\r\n* Transmural myocardial infarction within the  months of study registration\r\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\r\n* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
Chronic Obstructive Pulmonary Disease (COPD) exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration. COPD requiring chronic oral steroid therapy
Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within  calendar days prior to registration
Severe, active co-morbidity, defined as follows:\r\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last  months\r\n* Transmural myocardial infarction within the last  months\r\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of step  registration\r\n* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of step  registration\r\n* Severe hepatic disease, defined as a diagnosis of Child-Pugh class B or C hepatic disease\r\n* Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD) count <  cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD count >=  cells/microliter within  days prior to registration; note also that HIV testing is not required for eligibility for this protocol\r\n* End-stage renal disease (ie, on dialysis or dialysis has been recommended)
Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
Severe, active co-morbidity, defined as follows:\r\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last  months prior to registration\r\n* Transmural myocardial infarction within the last  months prior to registration\r\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\r\n* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within  days prior to registration\r\n* Severe hepatic disease, defined as a diagnosis of Child-Pugh class B or C hepatic disease\r\n* Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD)  count <  cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD count >=  cells/microliter within  days prior to registration; note also that HIV testing is not required for eligibility for this protocol\r\n* End-stage renal disease (i.e., on dialysis or dialysis has been recommended)
Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration
Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within  days before registration
Severe, active co-morbidity defined as follows:\r\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last  months\r\n* Transmural myocardial infarction within the last  months\r\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\r\n* Severe hepatic disease, defined as a diagnosis of Child-Pugh class B or C hepatic disease\r\n* Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD) count <  cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD count >=  cells/microliter within  days prior to registration; note also that HIV testing is not required for eligibility for this protocol\r\n* Other major medical illness which requires hospitalization or precludes study therapy at the time of registration
Severe illness requiring hospitalization
Severe, active co-morbidity, defined as follows:\r\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last  months\r\n* Transmural myocardial infarction within the last  months\r\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\r\n* Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within  days before registration\r\n* Human immunodeficiency virus (HIV) positive with cluster of differentiation (CD) count <  cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD count >=  cells/microliter within  days prior to registration; note also that HIV testing is not required for eligibility for this protocol\r\n* End-stage renal disease (i.e., on dialysis or dialysis has been recommended)
e. Unstable pulmonary disease requiring hospitalization or emergency room visit within the last  months.
Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within  weeks of registration
Chronic lung disease or Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration.
Patients with acute chronic obstructive disease exacerbation as the primary etiology for respiratory failure
Severe, active co-morbidity defined as follows:\r\n* Unstable angina and/or congestive heart failure requiring hospitalization within the last  months\r\n* Transmural myocardial infarction within the last  months\r\n* Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration\r\n* Chronic obstructive pulmonary disease exacerbation or other acute respiratory illness precluding study therapy at the time of registration\r\n* Severe hepatic disease defined as a diagnosis of Child-Pugh class B or C hepatic disease\r\n* Renal tubular acidosis or metabolic acidosis\r\n* Human immunodeficiency virus (HIV) positive with CD count <  cells/microliter; note that patients who are HIV positive are eligible, provided they are under treatment with highly active antiretroviral therapy (HAART) and have a CD count >=  cells/microliter within  days prior to registration; Note also that HIV testing is not required for eligibility for this protocol
Chronic Obstructive Pulmonary Disease (COPD) exacerbation or other respiratory illness requiring hospitalization or precluding study therapy within  days before registration
Serious illness requiring systemic treatment and/or hospitalization within  days prior to entry